HOUSTON--(BUSINESS WIRE)--SpinalCyte, LLC, a Texas-based regenerative medicine company focused on regrowth of the spinal disc using Human Dermal Fibroblasts (HDFs), today announced the issuance of new patents in the U.S. and Japan. The company’s patent portfolio now includes 39 U.S. and international patents issued with 100+ patents pending focused on the clinical use of fibroblasts. The company received IND clearance from the FDA in November to continue clinical trials into its lead fibroblast cell therapy product, CybroCell, in the treatment of degenerative disc disease.
“Our new patents demonstrate the versatility of our technology to repair cartilage not just in the spine, but throughout the body,” said Pete O’Heeron, Chief Executive Officer of SpinalCyte. “As the leader in the field of human dermal fibroblast therapy, we are excited to continue our clinical work to demonstrate the promise of HDFs for a variety of disease paths.”
The U.S. Patent No. 10,206,954 titled “Adipose Cells for Chondrocyte Applications,” and Japanese Patent No. 6456826 titled “Generation of Cartilage Ex Vivo From Fibroblasts” describe methods to differentiate adipose and fibroblast cells into cartilage using a mold to shape the tissue to replace damaged cartilage. Claims also include using a mixture of chondrocyte-like cells, adipose cells and growth factors delivered to a joint to repair damaged cartilage.
About Degenerative Disc Disease
Degenerative disc disease (DDD) is a condition in which a patient’s spinal disc breaks down and can begin to collapse. It is estimated that 85% of people over the age of 50 have evidence of disc degeneration and over 1.3 million procedures a year are performed to treat the disease. The most common treatments for patients with DDD are either discectomy or spinal fusion. Discectomy is the partial or full removal of the degenerated disc to decompress and relieve the nervous system but can cause long term spinal pain. In a spinal fusion procedure, the entire disc is removed and the two adjacent vertebrae are fused together. It often increases strain on the adjacent discs and surrounding tissues leading to further degeneration.
CybroCell is the first off-the-shelf allogenic human dermal fibroblast (HDF) product for the treatment of degenerative disc disease. SpinalCyte’s Phase 1/Phase 2 clinical trial for injected human dermal fibroblasts in the treatment of DDD demonstrated after 12 months, patients injected with CybroCell had sustained improvement in pain relief and increased back mobility.
Based in Houston, Texas, SpinalCyte, LLC, is a regenerative medicine company developing an innovative solution for spinal replacement using human dermal fibroblasts. Currently, SpinalCyte holds 39 U.S. and international issued patents and has filed for an additional 100+ patents pending and issued across a variety of clinical pathways, including disc degeneration, cancer, diabetes, liver failure and heart failure. Funded entirely by angel investors, SpinalCyte represents the next generation of medical advancement in cell therapy. Visit www.spinalcyte.com.